This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...